<DOC>
	<DOC>NCT00245258</DOC>
	<brief_summary>The study objective is to: 1. To evaluate the effect of sildenafil citrate versus placebo on the IIEF_EF Domain at the end of the double-blind phase 2. To assess the relationship between treatment with sildenafil citrate or placebo and responses to the Quality of Erection Questionnaire (QEQ) and Sexual Experience Questionnaire (SEX_Q).</brief_summary>
	<brief_title>Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Male subjects aged 1865. Documented clinical diagnosis of erectile dysfunction confirmed by an IIEFEF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEFEF Domain, screening procedures should be terminated.) Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE5) inhibitor such as vardenafil or tadalafil for erectile dysfunction [Note: subjects should not have taken any PDE5 inhibitors within 4 weeks prior to the date of screening].</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>